Associated Papers
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H et al.
Journal of Medicinal Chemistry, 2016
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
Giunti S et al.
International Journal of Endocrinology, 2013
Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Dixit A et al.
Biophysical Journal, 2009
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Carlomagno F et al.
Oncogene, 2004
Select a paper to view details